Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17471309 | 0.91 | SIGMAR1 (0.37) | SIGMAR1HRH3ABCB1 | |
| SCHEMBL24828001 | 0.90 | MEN1 (0.40) | — | |
| SCHEMBL10312572 | 0.90 | SIGMAR1 (0.42) | SIGMAR1HRH3ABCB1 | |
| SCHEMBL1106428 | 0.88 | ALDH1A1 (0.34) | HRH3 | |
| SCHEMBL18032457 | 0.87 | L3MBTL3 (0.35) | HRH3ABCB1 | |
| SCHEMBL26419480 | 0.87 | ABCB1 (0.33) | SIGMAR1HRH3ABCB1 | |
| SCHEMBL23180455 | 0.86 | CHRM2 (0.35) | HRH3 | |
| SCHEMBL18032444 | 0.85 | CYP2D6 (0.36) | SIGMAR1HRH3ABCB1 | |
| SCHEMBL18032450 | 0.85 | CYP2D6 (0.36) | SIGMAR1HRH3ABCB1 | |
| SCHEMBL18032453 | 0.85 | CYP2D6 (0.36) | SIGMAR1HRH3ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-04-01 | — | — | US | disclosed |
| US-9718825-B2 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2017-08-01 | — | — | US | disclosed |
| US-9718825-B2 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2017-08-01 | — | — | US | disclosed |
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-01-28 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | SIGMAR1 442/4885HRH3 2327/4885ABCB1 2010/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | SIGMAR1 3832/4885HRH3 1829/4885ABCB1 560/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | SIGMAR1 3832/4885HRH3 1829/4885ABCB1 560/4885 |
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | KRAS, NRAS, HRAS | SIGMAR1 3998/4885HRH3 2019/4885ABCB1 317/4885 |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | SIGMAR1 4655/4885HRH3 4050/4885ABCB1 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.